RBC Capital Reiterates Outperform on Perspective Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Perspective Therapeutics (AMEX:CATX) and maintained a $3 price target.
June 14, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Perspective Therapeutics (AMEX:CATX) and maintained a $3 price target, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $3 price target by RBC Capital suggests that the analyst has a positive outlook on Perspective Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100